While you’re here… help us stay here.

Are you enjoying open access to policy and research published by a broad range of organisations? Please donate today so that we can continue to provide this service.

Report
Report cover

The firm and the FDA: McKinsey and Company’s conflicts of interest at the heart of the opioid epidemic

Interim Majority Staff Report
Publisher
Conflict of interest Regulatory conflict Drug harmfulness Drug use Pharmaceuticals Opioids United States of America
Description

This interim staff report presents preliminary findings from the Committee’s investigation into McKinsey & Company’s (McKinsey) consulting services for opioid and pharmaceutical companies and McKinsey’s conflicts of interest. The Committee launched this investigation following reports that McKinsey engaged in abusive and deceptive business practices in driving the sales of prescription opioids—which have contributed to an epidemic that has killed more than half a million Americans—while also consulting for federal agencies regulating the opioid market.

The Committee’s investigation has uncovered significant, years-long conflicts of interest at McKinsey, resulting from its work for the federal government at the same time that it was advising opioid manufacturers. Documents show that one opioid manufacturer, Purdue Pharma (Purdue), explicitly tasked McKinsey with providing advice on how to influence the regulatory decisions of the U.S. Food and Drug Administration (FDA), another McKinsey client. The Committee’s investigation has uncovered evidence that McKinsey sought to use its government connections to solicit private sector business. The Committee has also obtained evidence suggesting that McKinsey sought to influence government officials, including Trump Administration Secretary of Health and Human Services (HHS) Alex Azar, to advance the interests of its private sector opioid clients.

Publication Details
Access Rights Type:
open